Implications for body weight extremes in solid organ transplantation.

Autor: Campara M; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, 60612, USA., Lourenco LM; University of Chicago, Chicago, IL, USA., Melaragno JI; University of Rochester Medical Center, Rochester, NY, USA., Kaiser TE; University of Cincinnati, Cincinnati, OH, USA.
Jazyk: angličtina
Zdroj: Pharmacotherapy [Pharmacotherapy] 2021 Jan; Vol. 41 (1), pp. 44-58. Date of Electronic Publication: 2021 Jan 19.
DOI: 10.1002/phar.2493
Abstrakt: The pharmacokinetic profiles of medications are altered in overweight and underweight patients, but few studies have described these differences in patients with body mass index extremes. As solid organ transplant programs expand their candidate selection criteria to accommodate a growing population of patients with weight extremes, it has become imperative to understand and evaluate the impact weight extremes have on the pharmacokinetics of life-sustaining immunosuppression in this population. This review will describe pharmacokinetic and dosing considerations for weight extremes in solid organ transplant recipients, including changes following bariatric surgeries, non-pharmacologic and pharmacologic management strategies for weight loss and gain, and potential drug-drug interactions with popular weight management products.
(© 2021 Pharmacotherapy Publications, Inc.)
Databáze: MEDLINE
Externí odkaz: